This is Galenicum

Galenicum was founded in Barcelona in 2003 by three friends in their twenties. Their mission was to provide quality and affordable Active Pharmaceutical Ingredients (APIs) to the Spanish pharmaceutical industry, emerging in the area of generics at that time.

Since then, the company has grown significantly to become a global ecosystem of several businesses within the pharmaceutical, food and nutritional supplement sectors, with current commercial footprint in over forty countries.

Galenicum remains committed to its original purpose of improving the quality and affordability of medicine: A non-stop challenge in becoming a global specialty pharmaceutical company.

Galenicum covers the full pharmaceutical value chain, including:

• Trading of Active Pharmaceutical Ingredients (APIs),

• Intellectual property and patents,

• Research and Development of Finished Dosage Forms (FDFs),

• Regulatory affairs,

• Manufacturing,

• Supply and Commercialisation.


'Believe in life' has been our company tag line for many years now and it is a statement of hope for people around the world who are facing health issues and, for whom, we devote our talent and effort here at Galenicum.

'Believe in life' is also a good reflection of our company's ‘can do’ and forward-looking attitude, which is truly embedded within our culture, well-present in our daily work.



Our Story
An adventure that started over 15 years ago to make high-quality affordable medicine: A non- stop challenge in becoming a global specialty pharmaceutical company.
  • 2003

    Galenicum founded in Barcelona

  • 2007

    First authorisation received for generic products in Spain

  • 2009

    Granting of the first patent to Galenicum

  • 2010

    Incorporation of the GSI subsidiary for food ingredients

  • 2012

    Setting up business in Chile, Peru and Brazil

  • 2013

    Acquisition of a manufacturing plant

  • 2014

    Recognised as 'Business of the Year' in the European Business Awards

  • 2015

    Dermatalogical business incorporated

  • 2016

    Launch of food supplement range

  • 2018

    First Galenicum-developed product approved by the USFDA Setting up business in Colombia

  • 2019

    Setting up business in Ecuador

  • 2020

    New growth plans: Doubling of revenues to reach 240 Million Euro by 2024


Thanks for your interest in Galenicum. We will get back to you if your profile is a match.